




RealRate

PHARMACEUTICAL 2019

Supernus Pharmaceuticals INC
Rank 180 of 361



The relative strengths and weaknesses of Supernus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Supernus Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Supernus Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is 265%, being 15% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	493,487
Cost of Goods Sold	15,356
Intangible Assets	31,368
Liabilities, Current	161,353
Liabilities, Non-Current	11,398
Other Assets	448,861
Other Compr. Net Income	-2,411
Other Expenses	29,183
Other Liabilities	352,037
Other Net Income	-4,268
Other Revenues	408,897
Property and Equipment	4,095
Research and Development	89,209
Selling, General and Administrative Expense	159,888

Output Variable	Value in 1000 USD
Assets	977,811
Liabilities	524,788
Expenses	293,636
Revenues	408,897
Stockholders Equity	453,023
Net Income	110,993
Comprehensive Net Income	109,788
BaseVar	1,105,906
ECR before Limited Liability	146%
Economic Capital Ratio	265%